Business Context and Reporting Period
This Form 8-K filing by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc. in metadata) covers a material event occurring on January 21, 2019, with the report filed on February 1, 2019. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing details a specific financing transaction rather than comprehensive financial statements. Key metrics include:
- Loan Amount Received: $500,000.
- Total Credit Facility: Revolving line of credit up to $1,000,000.
- Interest Rate: Prime rate plus 1% (Regular Interest Rate).
- Default Interest Rate: Prime rate plus 6% (5% penalty plus Regular Interest Rate).
- Maturity Date: January 1, 2020.
- Repayment Terms: Interest payable monthly starting February 1, 2019; full principal and accrued interest due at maturity. Prepayment is allowed without penalty.
- Collateral: Security interest granted in almost all assets of the Company and its wholly-owned subsidiary, American BriVision Corporation.
- Guarantees: Dr. Tsung Shann Jiang and Dr. George Lee provided individual commercial guarantees up to $500,000 each.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels outside of this new agreement.
Material Changes
The primary material change is the entry into a Material Definitive Agreement with Cathay Bank. This creates a new direct financial obligation and an off-balance sheet arrangement (via the guarantees) as of January 21, 2019. The Company has secured a revolving credit facility to support its operations, with the initial draw of $500,000 received on the reporting date.
Outlook, Risks, and Contingencies
Management Commentary: The filing indicates the Company is actively securing financing to support its business, including pending mergers with BioLite Holding, Inc. and BioKey, Inc., as disclosed in a prior 8-K filing.
Risks and Contingencies:
- Default Risk: Failure to meet payment obligations will trigger a significant increase in the interest rate (an additional 5%).
- Asset Encumbrance: The Company has pledged almost all of its assets and those of its subsidiary as collateral, limiting future borrowing capacity against these assets.
- Personal Liability: Key executives (Dr. Jiang and Dr. Lee) have personally guaranteed the debt, creating a direct financial link between management and the Company's solvency.
Investor Verification Checklist
- Verify the current status of the pending mergers with BioLite Holding, Inc. and BioKey, Inc. referenced in the guaranty section.
- Confirm the Company's ability to service the monthly interest payments starting February 1, 2019, given the lack of disclosed revenue in this filing.
- Review the full text of the Security Agreement (Exhibit 10.3) to understand specific exclusions from the "almost all assets" collateral pledge.
- Check for any subsequent filings regarding the utilization of the remaining $500,000 available under the revolving line of credit.